217 related articles for article (PubMed ID: 14663774)
1. Cardiac effects of adjuvant therapy for early breast cancer.
Theodoulou M; Seidman AD
Semin Oncol; 2003 Dec; 30(6):730-9. PubMed ID: 14663774
[TBL] [Abstract][Full Text] [Related]
2. Management of febrile neutropenia and cardiac toxicity in the adjuvant treatment of breast cancer.
O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 8 Suppl 1():S11-21. PubMed ID: 18282366
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
4. Cardiac risks in multimodal breast cancer treatment.
Budach W
Strahlenther Onkol; 2007 Dec; 183 Spec No 2():9-10. PubMed ID: 18166997
[No Abstract] [Full Text] [Related]
5. [Cardioprotective treatment during adjuvant cancer therapy].
Gulati G; Heck SL; Ree AH; Gravdehaug B; Røsjø H; Steine K; Bratland Å; Hoffmann P; Geisler J; Omland T
Tidsskr Nor Laegeforen; 2013 Sep; 133(17):1832-6. PubMed ID: 24042297
[TBL] [Abstract][Full Text] [Related]
6. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
[TBL] [Abstract][Full Text] [Related]
7. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
[TBL] [Abstract][Full Text] [Related]
8. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
9. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
Belkacémi Y; Gligorov J; Mauriac L; Azria D
Bull Cancer; 2006 Oct; 93(10):991-9. PubMed ID: 17074658
[TBL] [Abstract][Full Text] [Related]
10. [Current status of treatment for early-stage invasive breast cancer].
Kásler M; Polgár C; Fodor J
Orv Hetil; 2009 May; 150(22):1013-21. PubMed ID: 19465349
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
[TBL] [Abstract][Full Text] [Related]
12. Ongoing adjuvant trials with trastuzumab in breast cancer.
Tan AR; Swain SM
Semin Oncol; 2003 Oct; 30(5 Suppl 16):54-64. PubMed ID: 14613027
[TBL] [Abstract][Full Text] [Related]
13. Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?
Davidson A; Gelmon K
Future Oncol; 2011 Jan; 7(1):37-55. PubMed ID: 21174537
[TBL] [Abstract][Full Text] [Related]
14. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study.
Shaffer R; Tyldesley S; Rolles M; Chia S; Mohamed I
Radiother Oncol; 2009 Jan; 90(1):122-6. PubMed ID: 18976826
[TBL] [Abstract][Full Text] [Related]
15. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.
Kabe KL; Kolesar JM
Am J Health Syst Pharm; 2006 Mar; 63(6):527-33. PubMed ID: 16522889
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
17. Tomorrow's targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity?
Magné N; Chargari C; MacDermed D; Conforti R; Védrine L; Spano JP; Khayat D
Crit Rev Oncol Hematol; 2010 Dec; 76(3):186-95. PubMed ID: 20138541
[TBL] [Abstract][Full Text] [Related]
18. Re: Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
Magné N; Chargari C
Nat Clin Pract Oncol; 2008 Nov; 5(11):E1. PubMed ID: 18957967
[No Abstract] [Full Text] [Related]
19. Second cancers after breast cancer treatment.
Matesich SM; Shapiro CL
Semin Oncol; 2003 Dec; 30(6):740-8. PubMed ID: 14663775
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
